Therefore, therapeutic monitoring of IFNB in MS patients using RS and MRS would be also helpful to evaluate Asian MS populations, but the previous validation of RS and MRS was performed only in Western MS patients based mainly on a prospective research cohort [7,8]. The gene discussed is IFNB1; the disease is myeloid sarcoma.